Summary:
A randomized, double-blind, parallel group, multicenter study of the effects of an investigational medication on the rate of exacerbations of chronic obstructive pulmonary disease (copd).
Qualified Participants Must:
• Be one of the following:
Males and females of a minimum age of 40 years with a clinical diagnosis of COPD, a
≥10 pack-year smoking history, a pre-bronchodilator FEV1 < 70% of predicted normal
and a pre-bronchodilator FEV1/FVC ratio < 0.70, are eligible for study participation.
Moreover, eligible subjects must be recently (i.e. within 14 days) discharged from a ≤ 10-
day hospitalization for an acute exacerbation of COPD, or treated for an acute
exacerbation of COPD in the ER and held for observation for at least 24 hours. Also
eligible for participation are, patients who received oral corticosteroids or oral
corticosteroids and antibiotics for treatment of an exacerbation of COPD during a physician’s office or ER visit in the 14 days prior to randomization, AND who have been hospitalized within the previous six months due to an acute exacerbation of COPD.
Qualified Participants May Receive:
All study related medication and healthcare at no cost. Eligible participants will be compensated for their time and travel.